
News|Articles|May 1, 2002
Lercanidipine: A long-acting dihydropyridine calcium channel blocker for treatment of hypertension
Lercanidipine is currently under FDA review for the management of hypertension. In comparative clinical trials, lercanidipine has shown antihypertensive efficacy comparable to that of slow-release nifedipine, amlodipine, nitrendipine, verapamil, captopril, and atenolol. Its side effect profile is similar or superior to these agents. This Focus article reviews those trials as well as lercanidipine?s pharmacologic properties and addresses the agent?s potential role in patients with comorbid conditions.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Some employers steer workers toward cash platforms for GLP-1 obesity drugs
2
Trade group for transparent PBMs has changed its name
3
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
4
Health insurance without a net(work)
5


























